Stand aside — setup invalidated
Setup score 55, but distribution days reach 5 or more — stand aside until the condition resets.
Simple research view
INCY · Incyte Corporation
$123.28 -2.17% Sep 10 close
Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.
$INCY
Incyte CorporationIncyte Corporation is a Pharmaceuticals: Major company in the Health Technology sector.
Historical verdict · setup score 55/100 · data Sep 10 close · 1 session old
Stand aside — setup invalidated
Setup score 55, but distribution days reach 5 or more — stand aside until the condition resets.
Earnings
Normal technical setup
Next earnings
Monday, October 26, 2026
Report time not confirmed by the source
Deterministic evidence
INCY-2.17%
Sector proxy · XLV-0.55%
Broad market · SPY-0.60%
Session internals Weak
Rule: closed flat-to-down and in the bottom third of the range. Judged on internals, not on the size of the move.
Vs prior close-2.17%
From the open-1.45%
Range position19%
GapNo gap
QQQ confirmationConfirming (-1.06%)
SMH confirmationConfirming (-2.44%)
Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.
More stats
52W Low
$81.09
Tight Wks
0
Base
B3
SMA 200
$105.05
RS Line vs High
-7.2%
RS Line Slope
+5.0% ▲
Group Rank
#27/58
ADR%
2.6%
ATR(14)
$3.33 (2.7%)
Vol Pace (live)
N/A
U/D Vol
2.26
A/D Days
17A / 12D
A/D Rating
A+
VDU Bars
0/10 d
Earnings
in 44d
INCY Chart
Interactive price, volume, RS, RSI, and MACD charts are available after sign in.
Technical Analysis Report Card
$INCY · $123.28 · as of 2026-09-10 · multi-factor read
82
/ 100
Reference read from price & volume only — the verdict at the top of the page decides the action.
Trend · Daily / Weekly / Monthly
Daily
▬ Sideways / consolidating
Weekly
▲ Uptrend
Monthly
▲ Uptrend
Moving Averages
50-day$121.45 ↑
100-day$110.70 ↑
200-day$105.05 ↑
Bullish (50 > 200)
RSI (14)
Reading48.3 · Neutral
Neutral — momentum is balanced between buyers and sellers.
MACD (12/26/9)
StateWeakening
Histogram-0.655
Weakening — MACD slipped below its signal line. Histogram contracting.
Bollinger Bands (20,2)
%B / Width28% · 8.8%
Mid-band — no directional band edge in play.
Volume · Buyer vs Seller
Up/Down vol2.26 · Accumulation
Rel volume0.92×
Accumulation — volume is concentrated on up days; buyers dominate. Recent volume is easing versus its baseline.
Support & Resistance
R · $130.80swing level
R · $132.6052-week high
Price · $123.28now
S · $121.61swing level
S · $115.77swing level
S · $110.56swing level
Fibonacci · Uptrend swing
23.6% ◄ price here$122.37
38.2%$116.04
50.0%$110.92
61.8%$105.81
78.6%$98.53
Retracement support zones measured from the recent swing low up to the high.
The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for INCY — plus the full 500+ symbol scanner and Ask-the-Legends chat.
Start your 7-day free trial →
Weekly uptrendMonthly uptrendAbove 200-day MA50/200 bullishVolume accumulation
Want this read in a legend's voice?
Ask a Legend about INCY
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts
6 methodology checks
Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.
Council consensus:
5 of 6 legends are Watching — building, not yet a confirmed buy.
Watch
Minervini B
Trend-template read: 9/12 pass; wait for the soft misses to improve.
Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $123.28, MA150 $106.12, MA200 $105.05
1.2 150-day MA > 200-day MAMA150 $106.12 vs MA200 $105.05
Failing evidence
2. Quarterly EPS growth ≥ 25%From SEPA scan
2. ROE ≥ 17%From SEPA scan
Avoid
O'Neil D
CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.
Passing evidence
N: Near 52-week high or RS line new high7.0% below high | RS line new high: False
S: Base tightness (ATR% ≤ 4.5%)ATR% 2.70%
Failing evidence
C: Quarterly EPS acceleration ≥ 25%CANSLIM grade N/A
L: RS rank ≥ 80 (IBD leadership)RS rank 71
Watch
Weinstein C
Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.
Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $123.28 vs MA200 $105.05
Failing evidence
Volume expansion above averageVolume ratio 0.92x
Weekly price coiling (Stage 2 consolidation)Tightening weekly range confirms base
Watch
Livermore B
Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$123.28
Relative strengthRS 71
Failing evidence
Volume vs average0.92x
Pivotal point cleared on expanding volumeNot confirmed
Watch
Darvas B
Box-theory read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$123.28
Relative strengthRS 71
Failing evidence
Volume vs average0.92x
Box top broken on heavy volumeNot confirmed
Watch
Wyckoff B
Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$123.28
Relative strengthRS 71
Failing evidence
Volume vs average0.92x
Sign of Strength confirmed on expanding volumePrice hasn't cleared the pivot yet — confirmation pending
Base & Breakout
Breakout follow-through
No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?
RS Line vs SPY
52-week relative strength · blue = RS line · dashed = MA50 · dot = NH
▲ Rising
Accumulation / Distribution
last 65 sessions · green = acc on high vol · red = dist on high vol
Net +5
Fundamentals & leadership quality — Minervini’s published criteria · 2/7 met
C
2/7 criteria
Separate score from the Minervini Trend Template (8/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ
—
Revenue growth ≥20% YoY
+14%
Gross margin ≥30%
—
ROE ≥17%
—
RS rating ≥80 (leadership)
71
Stage 2 uptrend (Weinstein)
Stage 2
Within 25% of 52W high
-7.0%
Method Playbook
Trade it like Livermore
EXACT LEVELS · PRO
Livermore B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro levelPublished-method rule: Treat the resistance break as a pivotal point only while the primary trend and relative strength remain aligned.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro levelPublished-method rule: Wait for price and volume to confirm the pivotal-point break; anticipation below the line is not confirmation.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro levelPublished-method rule: Place the initial stop below the pivotal line or the reaction low that would prove the breakout false.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-basedPublished-method rule: Raise protection beneath successive higher reaction lows as the trend advances; never move a protective line farther away.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro levelPublished-method rule: Exit when price fails the pivotal line, breaks the latest meaningful reaction low, or shows abnormal reversal action.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →
Pattern Analysis (historical)
Darvas Box
Historical replay: +20% before −8% within 40 sessions: 18% (n=60) · source bars 2025-03-17–2026-09-04 · avg -0.2% per setup (-0.03R)
⚠ 3rd-stage base
⚠ Not actionable yet
55
setup score
RS Score
71
Trend template
8/8 ✓
CANSLIM
— (N/A)
box top: 130.8
box bottom: 121.61
box height pct: 0.076
vol ratio: 0.916
is breakout: ✗
pct from 52w high: 0.014
validation reason: valid generic setup
multi tf evaluated: ✓
multi tf reason: weekly: within 15% of 52-week high (Darvas box territory)
Why This Setup?
Darvas Box · schematic
Box: top=130.80, bottom=121.61, height=7.6%, breakout=no, vol_ratio=0.9x, 1% from 52w high | Strong trend (8/8) | Good RS (71) | Moderate pattern (65%) | Accumulation (2.3× up/dn vol) | Stage 2 | Readiness 60/100 (early) | CANSLIM N/A (N/A) | ⚠ 3rd-stage base; Not actionable yet
The Universal Edge Check · context only
What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.
2/7
universals met
- Risk is defined — not met No stop — undefined risk
- A relative-strength leader — partly met RS rank 66 — middling
- Asymmetric reward — partly met No target set
- Not chasing (in range) — partly met Pivot distance unknown
- Volume confirms — partly met 0.9× average — light
- Clear of earnings — met in 44 days
- In a confirmed uptrend — met Stage 2 · Trend template 8/8
Minervini Trend Template
8/8 ✓Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.
Price above SMA 150 & 200
$123.28 vs SMA150 $106.12 / SMA200 $105.05
SMA 150 above SMA 200
SMA150 $106.12 vs SMA200 $105.05
SMA 200 trending up
Slope +2.49 over 20 days
SMA 50 above SMA 150 & 200
SMA50 $121.45
Price above SMA 50
$123.28 vs SMA50 $121.45
30%+ above 52-week low
+52.0% from $81.09
Within 25% of 52-week high
-7.0% from $132.60
RS score above 70
RS 71
Fundamentals
52W Range
82%
Rev YoY
+14%
Company
Company profile
Incyte Corporation
CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market
N/A
— CANSLIM
C · Curr. EPS
70
A · Annual EPS
71
N · New Highs
100
S · Supply/Demand
70
L · Leader RS
71
I · Inst. Spons.
100
M · Market
30
Weekly Context
Multi-timeframe signals from weekly barsW. Trend
8/8
W. RS
90
W. Support
$89.25
W. Resist
$132.60
Weekly Structure
Trend
Neutral
Tight Weeks
0
Confirmation
Neutral
Scan History
Sep 11
Darvas Box
✓ Gate
55
Sep 10
Trend Only
✓ Gate
81
0.0%
Sep 10
Darvas Box
✓ Gate
77
0.0%
Sep 09
Trend Only
✓ Gate
83
-2.2%
Sep 09
Trend Only
✓ Gate
82
-2.2%
Get the full picture on INCY
Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.
Start 7-Day Free Trial